Rockefeller & Co analyst David Song sees a lot of healthcare companies coming out ahead in the event the new healthcare reform bill passes Congress. In particular, he cites Amgen and Alexion as two of the biotech industry's biggest winners. Both companies, he tells Barron's, have new drugs that will benefit from the bill's provision for marketing exclusivity. Report